The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of the body, shipped to a specialized facility, genetically reprogrammed, ...

A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer ...

Scientists have developed a method to reprogram cancer-fighting immune cells directly inside the body, potentially eliminating the need for complex lab-based manufacturing. Early results show rapid ...

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...

Cancer-fighting T cells do not simply "run out of energy." They are molecularly reprogrammed. For years, mitochondrial ...

Foundational research led by co-founder Justin Eyquem, Ph.D., underpins Azalea’s proprietary in vivo CAR T platformPeer-reviewed publication ...

The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells engineered inside the human body, a mouse study has found. Cancer-fighting ...

A breakthrough in CAR-T therapy may allow cancer treatment with a single injection, cutting costs and making care more available.

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...